We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
Read MoreHide Full Article
Pacific Biosciences of California (PACB - Free Report) closed at $1.38 in the latest trading session, marking a +2.99% move from the prior day. This change outpaced the S&P 500's 1.14% gain on the day. Meanwhile, the Dow gained 0.61%, and the Nasdaq, a tech-heavy index, added 1.69%.
The maker of genetic analysis technology's stock has climbed by 5.51% in the past month, exceeding the Medical sector's loss of 0.26% and the S&P 500's loss of 2.85%.
The upcoming earnings release of Pacific Biosciences of California will be of great interest to investors. On that day, Pacific Biosciences of California is projected to report earnings of -$0.13 per share, which would represent a year-over-year decline of 8.33%. Simultaneously, our latest consensus estimate expects the revenue to be $37.86 million, showing a 1.51% drop compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.43 per share and revenue of $156.1 million, indicating changes of +18.87% and -2.44%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pacific Biosciences of California. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Pacific Biosciences of California holds a Zacks Rank of #4 (Sell).
The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 102, placing it within the top 42% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
Pacific Biosciences of California (PACB - Free Report) closed at $1.38 in the latest trading session, marking a +2.99% move from the prior day. This change outpaced the S&P 500's 1.14% gain on the day. Meanwhile, the Dow gained 0.61%, and the Nasdaq, a tech-heavy index, added 1.69%.
The maker of genetic analysis technology's stock has climbed by 5.51% in the past month, exceeding the Medical sector's loss of 0.26% and the S&P 500's loss of 2.85%.
The upcoming earnings release of Pacific Biosciences of California will be of great interest to investors. On that day, Pacific Biosciences of California is projected to report earnings of -$0.13 per share, which would represent a year-over-year decline of 8.33%. Simultaneously, our latest consensus estimate expects the revenue to be $37.86 million, showing a 1.51% drop compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.43 per share and revenue of $156.1 million, indicating changes of +18.87% and -2.44%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pacific Biosciences of California. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Pacific Biosciences of California holds a Zacks Rank of #4 (Sell).
The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 102, placing it within the top 42% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.